CD4+CD57+ T Cell Assay for Costimulation Blockade Rejection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack predictive assays to identify patients at risk for costimulation blockade resistant rejection in transplant patients, particularly those receiving costimulation blockade therapy, which can lead to acute rejection complications.
Innovation Solution
A method involving the acquisition of a blood sample to quantify and compare the percentage of CD4+CD57+ T cells, where an elevated percentage indicates a risk for costimulation blockade resistant rejection, using multiparameter flow cytometry to analyze markers of senescence and exhaustion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If costimulation blockade therapy is used to prevent T-cell activation, then long-term graft function and patient survival are improved, but patients experience early acute rejection
Solution Approach 1:
The patent applies preliminary action by measuring CD57+ T cell percentages before transplantation to predict which patients are at risk for costimulation blockade resistant rejection. This pre-assessment allows clinicians to identify high-risk patients in advance and adjust their immunosuppressive regimens accordingly, preventing acute rejection before it occurs while maintaining the benefits of costimulation blockade therapy for long-term graft function.
2Loss of information
If CD57+ T cell percentage is measured to predict rejection risk, then patient stratification for costimulation blockade therapy is enabled, but additional diagnostic complexity is introduced
Solution Approach 1:
The patent replaces complex functional assays with a simpler flow cytometry-based measurement of CD57 surface marker expression on T cells. This substitution maintains predictive accuracy for rejection risk while significantly reducing diagnostic complexity, as flow cytometry is a standard, widely available technique that can quantify CD57+ T cell percentages without requiring complex experimental procedures.
Data Source
AI summary
The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or maintenance of a transplant.